Make confident, informed decisions with accurate HER2 measurements

INSIGHT

Recent advances in antibody-drug conjugates (ADCs) demand more nuanced classifications of the full spectrum of HER2. However, reproducibility of manual HER2-low and -ultralow scoring is challenged due to a scoring classification not feasible for the human eye. A better way to score HER2 is required.

Introducing our new, fully automated HER2 algorithm: Enabling precise quantification of expression across the complete spectrum

Find trace levels of HER2, easier

- Quantify HER2 membrane expression of every tumor cell – in biopsies as well as resections
- Identify real negatives by separating '0-no staining' from '0-with membrane staining'
- Stop searching for a single positive cell – use the intuitive heatmap for marker localization

Finish your HER2 reports effortlessly and efficiently

- Compatible with digital IMS/PACS workflows (integrated) or as standalone (web, on-prem or hybrid) with access to a slide scanner
- Fully automated analysis and built-in artefact exclusion
- Biomarker Reporting Template compatibility, with option for bi-directional communication of results through your existing IT systems

Stop eye-balling - measure exactly how close you are to the cutoffs

- Continuous, quantitative measurement of membrane completeness and intensity distributions
- Aligned with the 2023 ASCO/CAP guidelines to support scoring of the full HER2 spectrum (0 no staining, 0 with membrane staining (<10%), 1+, 2+ and 3+)
- Higher reproducibility than the human eye is capable of.

82%
overall agreement with pathologists scoring, reducing 2+ scores by up to **40%** (FISH confirmed)

96%
agreement with pathologists scoring of HER2 1+

Ready to spend less time zooming in?

Stay confident

VISIOPHARM®

For research use only. Not for use in diagnostic procedures

16737_03_2025